Latest Insider Transactions at Travere Therapeutics, Inc. (TVTX)
This section provides a real-time view of insider transactions for Travere Therapeutics, Inc. (TVTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Travere Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Travere Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 03
2023
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,091
-3.71%
|
$24,728
$8.25 P/Share
|
|
Sep 05
2023
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
457
-0.9%
|
$6,398
$14.71 P/Share
|
|
Sep 05
2023
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
4,455
-1.8%
|
$62,370
$14.71 P/Share
|
|
Sep 05
2023
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
1,815
-3.03%
|
$25,410
$14.71 P/Share
|
|
Sep 05
2023
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
1,815
-2.88%
|
$25,410
$14.71 P/Share
|
|
Aug 31
2023
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
9,900
+3.85%
|
-
|
|
Aug 31
2023
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
BUY
Grant, award, or other acquisition
|
Direct |
3,300
+5.22%
|
-
|
|
Aug 31
2023
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
BUY
Grant, award, or other acquisition
|
Direct |
3,300
+4.98%
|
-
|
|
May 17
2023
|
Ron Squarer |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+16.74%
|
-
|
|
May 17
2023
|
Suzanne Louise Bruhn |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+22.22%
|
-
|
|
May 17
2023
|
Gary A Lyons |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+9.18%
|
-
|
|
May 17
2023
|
John A Orwin |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+16.74%
|
-
|
|
May 17
2023
|
Jeffrey A Meckler |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+5.7%
|
-
|
|
May 17
2023
|
Brinkley Ruth Williams |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+26.09%
|
-
|
|
May 17
2023
|
Timothy Coughlin |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+9.57%
|
-
|
|
May 17
2023
|
Sandra Poole |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+20.93%
|
-
|
|
May 17
2023
|
Roy D. Baynes |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+15.52%
|
-
|
|
May 11
2023
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
122
-0.29%
|
$1,952
$16.12 P/Share
|
|
May 10
2023
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
825
-1.44%
|
$13,200
$16.59 P/Share
|
|
May 10
2023
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
455
-0.88%
|
$7,280
$16.59 P/Share
|
|
May 10
2023
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
436
-1.02%
|
$6,976
$16.59 P/Share
|
|
May 10
2023
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
825
-1.37%
|
$13,200
$16.59 P/Share
|
|
Apr 11
2023
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
47
-0.09%
|
$987
$21.49 P/Share
|
|
Feb 02
2023
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
360
-0.83%
|
$7,920
$22.42 P/Share
|
|
Feb 01
2023
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
2,590
-4.31%
|
$56,980
$22.25 P/Share
|
|
Feb 01
2023
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,779
-2.12%
|
$37,359
$21.75 P/Share
|
|
Feb 01
2023
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
2,590
-4.14%
|
$56,980
$22.25 P/Share
|
|
Feb 01
2023
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,588
-2.99%
|
$33,348
$21.75 P/Share
|
|
Feb 01
2023
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
8,196
-3.34%
|
$180,312
$22.25 P/Share
|
|
Feb 01
2023
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
1,671
-3.73%
|
$35,091
$21.75 P/Share
|
|
Jan 31
2023
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
BUY
Grant, award, or other acquisition
|
Direct |
20,250
+25.23%
|
-
|
|
Jan 31
2023
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
20,250
+19.45%
|
-
|
|
Jan 31
2023
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
BUY
Grant, award, or other acquisition
|
Direct |
20,250
+24.43%
|
-
|
|
Jan 31
2023
|
Jula Inrig CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
20,250
+34.91%
|
-
|
|
Jan 31
2023
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
20,250
+27.6%
|
-
|
|
Jan 31
2023
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
97,500
+28.44%
|
-
|
|
Jan 31
2023
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+18.24%
|
-
|
|
Jan 25
2023
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
192
-0.55%
|
$4,032
$21.63 P/Share
|
|
Jan 24
2023
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,550
-2.38%
|
$32,550
$21.9 P/Share
|
|
Jan 24
2023
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
852
-2.53%
|
$17,892
$21.9 P/Share
|
|
Jan 24
2023
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
6,442
-4.18%
|
$135,282
$21.5 P/Share
|
|
Jan 24
2023
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
2,062
-4.93%
|
$43,302
$21.5 P/Share
|
|
Jan 24
2023
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
2,062
-4.64%
|
$43,302
$21.5 P/Share
|
|
Jan 24
2023
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
905
-2.52%
|
$19,005
$21.9 P/Share
|
|
Jan 05
2023
|
Jula Inrig CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
442
-2.46%
|
$8,840
$20.75 P/Share
|
|
Jan 05
2023
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
5,625
-3.52%
|
$112,500
$20.75 P/Share
|
|
Jan 04
2023
|
Jula Inrig CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,051
-10.26%
|
$41,020
$20.75 P/Share
|
|
Sep 13
2022
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
349
-0.96%
|
$9,772
$28.0 P/Share
|
|
Sep 01
2022
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+12.91%
|
-
|
|
May 12
2022
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
1,050
-2.45%
|
$22,050
$21.51 P/Share
|